Structured evidence table for Lutein Focus Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Lutein Focus Randomized Trial | Results Across the 9 RCTs, lutein-containing supplementation significantly improved MPOD (Hedges' g = -0.589, p p = 0.001). | 1 | Wang WX (2026) | From Supplements to Sight: Quantifying the Impact of Lutein and Carotenoid on Age-Related Macular Degeneration-A Systematic Review and Meta-Analysis of Randomized Controlled Trials. |
| Lutein Focus Randomized Trial | Contrast sensitivity and serum lutein concentrations also improved significantly. | 1 | Wang WX (2026) | From Supplements to Sight: Quantifying the Impact of Lutein and Carotenoid on Age-Related Macular Degeneration-A Systematic Review and Meta-Analysis of Randomized Controlled Trials. |
| Lutein Focus Randomized Trial | Conclusion Lutein-based supplementation is associated with measurable structural and functional visual benefits in early-stage AMD. | 1 | Wang WX (2026) | From Supplements to Sight: Quantifying the Impact of Lutein and Carotenoid on Age-Related Macular Degeneration-A Systematic Review and Meta-Analysis of Randomized Controlled Trials. |
| Lutein Focus Randomized Trial | Purpose To quantify the effects of lutein-containing supplementation on structural and functional visual outcomes in patients with age-related macular degeneration (AMD), with particular focus on disease stage and treatment exposure. | 1 | Wang WX (2026) | From Supplements to Sight: Quantifying the Impact of Lutein and Carotenoid on Age-Related Macular Degeneration-A Systematic Review and Meta-Analysis of Randomized Controlled Trials. |
| Lutein Focus Randomized Trial | 7 9 The standard of care for many IRDs has largely focused on managing associated complications and the use of optical aids to improve quality of life. | 4 | Barthelemy Normila (2026) | Nutritional supplements: current evidence for retinitis pigmentosa and Stargardt disease |
| Lutein Focus Randomized Trial | This review synthesizes both historical and contemporary evidence regarding dietary and nutritional interventions for IRDs.  14 Retinitis pigmentosa is one of the most common IRDs and is characterized by progressive photoreceptor cell death. | 4 | Barthelemy Normila (2026) | Nutritional supplements: current evidence for retinitis pigmentosa and Stargardt disease |
| Lutein Focus Randomized Trial | By applying next-generation sequencing (NGS) technology to DNA samples stored from patients of the previous vitamin A trials, they were able to identify the specific RP gene variants for most participants and the lack of protective effect across genetic subtypes such as,and-associated retinitis pigmentosa []. | 4 | Barthelemy Normila (2026) | Nutritional supplements: current evidence for retinitis pigmentosa and Stargardt disease |
| Lutein Focus Randomized Trial | 1 4 5 6 Inherited retinal diseases (IRDs) comprise a complex group of heterogenous disorders that lead to progressive retinal cell death and functional vision loss. | 4 | Barthelemy Normila (2026) | Nutritional supplements: current evidence for retinitis pigmentosa and Stargardt disease |
Source documents